Nymox Pharmaceutical Corp News - NYMX

Nymox Officially Granted Extension to Regain Listing Requirements

IRVINE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the...

Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review

IRVINE, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...

NYMOX Appeals Deficiency Letter

IRVINE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX...

NYMOX Announces New Marketing Submission for NYMOZARFEX™ for BPH

IRVINE, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the...

May 2023 Market Cap Requirement Update

IRVINE, Calif., Nov. 25, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the...

Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)

0001018735true--12-31Q32022000010187352022-01-012022-09-300001018735nymox:JamesGRobinsonMember2022-06-300001018735nymox:JamesGRobinsonMember2022-01...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...

NYMOX Provides Current Update

IRVINE, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased...

NYMOX Updates Shareholders

IRVINE, Calif., July 15, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today...

NYMOX Receives Deficiency Letter from NASDAQ

IRVINE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to...

NYMOX Receives RTF letter from FDA

IRVINE, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

0001018735false--12-31Q1202200P0Y00010187352022-01-012022-03-310001018735nymox:SubsequentEventsMember2022-04-290001018735nymox:JamesGRobinsonMember...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Nymox Pharmaceutical Corp (NYMX)

Empower your portfolio: Real-time discussions and actionable trading ideas.

NYMX News

Nymox Officially Granted Extension to Regain Listing Requirements

Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review